top of page
Search

'Single author production' to an initial IND

  • Writer: Jaemin Cho
    Jaemin Cho
  • Mar 3, 2023
  • 2 min read

I had convinced myself for a prolonged period of time that utilizing a single author system would be the superior approach for compiling an initial IND package, which required over 70 separate documents to be authored to ensure complete coverage.


Although confident in my ‘single author production’, I was not solitary. For several years, I had worked hard as a regulatory affairs manager or director to make progress in the initial IND applications in which expertise in three different areas (cmc, nonclinical and clinical studies) was demanded.


Engagement with the three different areas had begun with the readings of FDA guidance materials. I have to admit that the tireless history of understanding in multiple areas had cast a persistent doubt over my approach which had not been broken anyway.


My approach was reaffirmed (by myself) following the more IND packages made in success.


While I was there, no one in the regulatory service companies had any advertisers saying that we would certainly make progress by single author production on any IND packaging issue. Instead, all seemed to agree it could be done best by multiple writers system.


That might be correct, however, I would like to emphasize that single author production is bound to yield certain advantages.


A single author system has one experienced writer responsible for writing data to a document. The benefit of a single writer system is that it provides strong consistency guarantees, meaning that all readers see the same version of documents. Since there is only one writer, there is no possibility for conflicting updates, which simplifies the coordination and synchronization required for updates. I believe maintaining consistency is crucial when preparing an IND package, where multiple documents are compiled under a single topic to support.


On the other hand, multiple writers system can offer higher write throughput and better scalability, since multiple writers can write to the system in parallel. This approach is often used in mass production, where multiple IND packages need to be written within a shared time frame. Thus, ensuring consistency in a multiple writer system can be more challenging, and conflicts between concurrent writes must be carefully managed to prevent inconsistencies.


An additional benefit pertains to the costs. One of the most common ways to save costs in a business is by reducing the amount of labor required to perform a task. The single author system is designed to focus on one or two IND packages. From the user or sponsor's point of view, it can bring quality improvement at a rather low cost.


To sum up, opting for a single author production offers benefits rather than risks. I say this in a sincere heart, having acted as a single author for several initial IND projects.

 
 
 

Recent Posts

See All
신약 개발 스타트업이 새겨야 할 조직

‘시작이 반이다’라는 속담이 있다. 어디에도 그 기원을 특정하기는 어렵지만, 오래전부터 우리 사회에서 사용되어 온 만큼, 농경 사회를 바탕으로 살아온 우리 조상들의 경험과 지혜를 담고 있다고 볼 수 있을 것이다. 농사는 씨앗을 뿌리는 것으로...

 
 
 
FDA 제출 문서 영문 번역

영문 문서는 국제적인 소통의 필수 도구다. 신약 개발 회사의 경우, 영문 논문 발표, 특허 출원, 임상 시험 보고서 작성 등 다양한 영역에서 영문 문서가 활용된다. 또한, 글로벌 규제 기관과의 소통을 위해서도 정확하고 명확한 영문 문서 작성 능력...

 
 
 
CLIA

임상 연구에서 정확하고 신뢰할 수 있는 검사는 중요하다. 검사 결과는 질병 진단, 환자 건강 상태 모니터링과 치료 결정에 기준이 되기 때문이다. 나라마다 기준이 있겠지만, 미국에서는 이러한 임상 검사의 최고 표준을 유지하고 안전성을 보장하기 위해...

 
 
 

Comments


bottom of page